Pharma Stocks
-
Branded Pharmaceuticals Stocks Q4 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in…
Read More » -
Sun Pharma-Organon deal: Outlook is mixed
Sun Pharma’s agreement to acquire all outstanding shares of NYSE-listed Organon & Co for $14 per share in a cash…
Read More » -
Pharma stock jumps 9% after signing $11.75 Bil deal to acquire US-based firm
Synopsis:- Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon & Co. for $14 per share in an…
Read More » -
Sun Pharma shares jump over 7% after firm announces plan to acquire US-based Organon at $11.75 billion valuation
Upstox Securities Pvt. Ltd.: SEBI Registration No. INZ000315837 | NSE TM Code: 13942 | BSE TM Code: 6155 | CDSL…
Read More » -
Is its pharma packaging moat strong enough to unlock new upsid
As demand for drug delivery systems surges globally, can Gerresheimer’s specialized manufacturing edge deliver reliable returns for you? This report…
Read More » -
Why Google Discover changes matter more now
Google’s 2026 Discover Core Update is reshaping how you access AstraZeneca plc stock (GB0009895292) insights on mobile, pushing personalized pharma…
Read More » -
Why Google’s 2026 Discover update matters more now for pharma in
Google’s 2026 Discover Core Update pushes personalized, mobile-first financial content on Almirall S.A. stock (ES0157097017) directly into your feed, giving…
Read More » -
InnoCare Pharma Limited Just Missed Revenue By 19%: Here’s What Analysts Think Will Happen Next
Last week, you might have seen that InnoCare Pharma Limited (HKG:9969) released its first-quarter result to the market. The early…
Read More » -
A Look At Corcept Therapeutics (CORT) Valuation After Lifyorli’s FDA Approval And Upcoming ROSELLA Phase 3 Data
Corcept Therapeutics (CORT) is back in focus after securing FDA approval for Lifyorli in platinum-resistant ovarian cancer and scheduling Phase…
Read More » -
Regeneron Stock: FDA Approval, Pricing Deal, and a Phase 3 Win in the Same Week
Key Stats for Regeneron Stock 52-Week Range: $476 to $821 Current Price: $752 Street Mean Target: $878 Street High Target:…
Read More »